Switch theme
Sign up to access all valuation multiples
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
2016
1.3K+
LTM Revenue $291M
LTM EBITDA -$8.5M
$335M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fulgent Genetics has a last 12-month revenue of $291M and a last 12-month EBITDA of -$8.5M.
In the most recent fiscal year, Fulgent Genetics achieved revenue of $283M and an EBITDA of -$49.0M.
Fulgent Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fulgent Genetics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $289M | $283M | XXX | XXX | XXX |
| Gross Profit | $367M | $104M | XXX | XXX | XXX |
| Gross Margin | 127% | 37% | XXX | XXX | XXX |
| EBITDA | -$49.2M | -$49.0M | XXX | XXX | XXX |
| EBITDA Margin | -17% | -17% | XXX | XXX | XXX |
| Net Profit | $143M | -$168M | XXX | XXX | XXX |
| Net Margin | 50% | -59% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fulgent Genetics's stock price is $19.
Fulgent Genetics has current market cap of $585M, and EV of $335M.
See Fulgent Genetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $585M | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fulgent Genetics has market cap of $585M and EV of $335M.
Fulgent Genetics's trades at 1.2x LTM EV/Revenue multiple, and -39.6x LTM EBITDA.
Analysts estimate Fulgent Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fulgent Genetics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $335M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | -6.8x | XXX | XXX | XXX |
| P/E | -13.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFulgent Genetics's NTM/LTM revenue growth is 10%
Fulgent Genetics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Fulgent Genetics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fulgent Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fulgent Genetics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -8% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 64% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fulgent Genetics acquired XXX companies to date.
Last acquisition by Fulgent Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Fulgent Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Fulgent Genetics founded? | Fulgent Genetics was founded in 2016. |
| Where is Fulgent Genetics headquartered? | Fulgent Genetics is headquartered in United States of America. |
| How many employees does Fulgent Genetics have? | As of today, Fulgent Genetics has 1.3K+ employees. |
| Who is the CEO of Fulgent Genetics? | Fulgent Genetics's CEO is Mr. Ming Hsieh. |
| Is Fulgent Genetics publicy listed? | Yes, Fulgent Genetics is a public company listed on NAS. |
| What is the stock symbol of Fulgent Genetics? | Fulgent Genetics trades under FLGT ticker. |
| When did Fulgent Genetics go public? | Fulgent Genetics went public in 2016. |
| Who are competitors of Fulgent Genetics? | Similar companies to Fulgent Genetics include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Fulgent Genetics? | Fulgent Genetics's current market cap is $585M |
| What is the current revenue of Fulgent Genetics? | Fulgent Genetics's last 12-month revenue is $291M. |
| What is the current EBITDA of Fulgent Genetics? | Fulgent Genetics's last 12-month EBITDA is -$8.5M. |
| What is the current EV/Revenue multiple of Fulgent Genetics? | Current revenue multiple of Fulgent Genetics is 1.2x. |
| What is the current EV/EBITDA multiple of Fulgent Genetics? | Current EBITDA multiple of Fulgent Genetics is -39.6x. |
| What is the current revenue growth of Fulgent Genetics? | Fulgent Genetics revenue growth between 2023 and 2024 was -2%. |
| Is Fulgent Genetics profitable? | Yes, Fulgent Genetics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
